Verve Therapeutics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2020
Period Ending	Aug '25 Aug 4, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2020
Market Capitalization	331,637	177,174	229,903	305,841	304,539	-	Upgrade
Market Cap Growth	9.05%	-22.93%	-24.83%	0.43%	-	-	Upgrade
Enterprise Value	303,872	143,690	196,350	278,886	260,519	-	Upgrade
Last Close Price	77.00	41.35	52.95	71.05	72.05	-	Upgrade
PE Ratio	20.36	10.86	32.63	-	-	-	Upgrade
Forward PE	14.57	8.23	15.51	-	-	-	Upgrade
PS Ratio	2.38	1.31	1.84	2.87	3.06	-	Upgrade
PB Ratio	4.71	2.68	4.25	6.79	5.50	-	Upgrade
P/TBV Ratio	4.79	2.73	4.35	6.99	5.65	-	Upgrade
P/FCF Ratio	-	7.66	13.14	-	-	-	Upgrade
P/OCF Ratio	-	5.59	10.04	340.30	-	-	Upgrade
EV/Sales Ratio	2.18	1.06	1.57	2.62	2.62	-	Upgrade
EV/EBITDA Ratio	15.74	7.62	17.73	-	-	-	Upgrade
EV/EBIT Ratio	20.49	9.95	29.94	-	-	-	Upgrade
EV/FCF Ratio	-	6.22	11.22	-	-	-	Upgrade
Debt / Equity Ratio	0.33	0.35	0.24	0.33	0.30	-1.19	Upgrade
Debt / EBITDA Ratio	1.22	1.04	0.89	-	-	-	Upgrade
Debt / FCF Ratio	-	0.99	0.74	-	-	-	Upgrade
Asset Turnover	1.05	1.03	1.16	1.04	1.12	1.39	Upgrade
Quick Ratio	0.92	1.03	1.21	1.10	1.38	1.33	Upgrade
Current Ratio	1.01	1.05	1.24	1.13	1.42	1.36	Upgrade
Return on Equity (ROE)	25.78%	27.62%	14.39%	-32.23%	-	-	Upgrade
Return on Assets (ROA)	6.99%	6.89%	3.80%	-7.69%	-23.93%	-15.18%	Upgrade
Return on Capital (ROIC)	11.48%	11.75%	6.55%	-12.53%	-38.57%	-26.00%	Upgrade
Return on Capital Employed (ROCE)	16.70%	17.00%	10.30%	-	-	-	Upgrade
Earnings Yield	4.91%	9.21%	3.06%	-5.06%	-31.47%	-	Upgrade
FCF Yield	-	13.05%	7.61%	-1.59%	-5.35%	-	Upgrade
Buyback Yield / Dilution	-	0.79%	-4.40%	-10.98%	-311.60%	0.31%	Upgrade

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.